Is that really pharmaceutical grade cannabis?

Cannabis has many different modes of delivery and applications for use. The most common ways that cannabis is used in our society today are: a smokeable, an edible, an oil or infused product. According to most market researchers, flower products and concentrates are the top sellers, with edibles and cosmetics also representing a solid segment of the market.[1] With new, innovative applications coming to market all the time, there is a whole world of cannabis derived products available to the public. When one thinks about the contamination that can happen during the production of these goods, either directly from the cannabis plant or from the processes surrounding how the products are made, it is easy to identify failures that have the potential to contaminate the products that patients and consumers are buying.

The laws for testing cannabis goods are at an early stage. There is considerable variation when it comes to the regulations regarding testing of cannabis products for contamination. The industry is still struggling to define what cannabis is and how to test the multitude of finished goods made with it. What does that mean? Simply put, the cannabis patients are buying for medicinal use is most likely not being tested to the pharmaceutical standards that one would expect. Furthermore, the edible, cosmetics and oils for vaping are coming out of a sparsely regulated industry that is still trying to catch up to the type of finished goods testing expected from every other industry. The industry needs to be testing our finished goods in a way that makes sense for the end user of the product. For example, testing raw cannabis flower or oils for common pathogenic mold and other organisms is a great place to start. However, if we are not testing our cosmetics, lotions, tinctures, suppositories, inhalers, and brownies in a way that reflects the processes and environments they are being made in, or the intended user, we are neglecting the overall safety of that product. Testing our cannabis raw materials to make sure it is safe is really only just the beginning.

Thankfully, there are cannabis clinicians and professionals who understand the importance of this topic. There are significant hurdles however that need to be addressed. Here are some of the major impediments to the collective ability to properly regulate the cannabis market.

  1. Federal Prohibition Laws

2020 is poised to be the year Americans finally stop saying if and can in full confidence start talking about when cannabis prohibition will end on a federal level. The most recent projections estimate that 90% of the US population will be living in a jurisdiction with some form of legal cannabis by the end of the year. The states are asking for FDA support when it comes to drafting testing requirements. Furthermore, most states simply do not have the resources required to properly enforce the laws that have been written. The cannabis industry needs the support of the federal government to help ensure that the products and medications are safe in all applications.

  • Variance in Regulations From State to State

The lack of oversight in the industry as a whole has led to a wide variety of legal requirements from state to state. This patchwork of regulations has made an already complicated discussion even more confusing. There are states requiring broad testing while other states have little to no regulatory requirements at all. Ultimately, this only jeopardizes the public. The industry is selling millions of dollars of product to the public that may or not be safe for human and/or animal consumption.

  • The Idea That “Cannabis Doesn’t Make People Sick.”

There is medical research out there that supports what many already believe, cannabis can be an amazing therapy for a whole host of diseases and disorders. [2] The type of testing being called for in this article does not speak to the efficacy of the plant as medicine, but instead protects users from the contamination that can be introduced to the finished good during the production and processing steps. Microbial contamination is not a function of the plant, but compromised product does contribute to disease and death.[3] Additives, heavy metals and pesticides are part of the process for creating many of the products on the market and those components have the potential to injure and even kill.

  • “We Can’t Afford It!”

This is a hard one. Many of the people in this industry have fought for years and even decades to move cannabis into a legal landscape. No small number of the people in the cannabis industry are involved because of a personal story of healing or comfort that lead to a passion to make cannabis accessible to all. At the same time, the businesses are fighting to be profitable. Testing is expensive and companies can feel that they have been delivering safe product with no problems for a long time. Some may be asking, “Why do we have to change now?” The reality remains though; immunocompromised and pediatric patients are more vulnerable than the general population. The testing requirements for products labeled as medicine and sold as such must ensure safety. The general public has an expectation of minimum safety thresholds for goods sold at large. The vaping crisis shows how quickly a small lapse in vigilance can have deadly and costly consequences. The industry is very young and competitor industries will be quick to capitalize on any opportunities to malign cannabis. Through thoughtfully written regulations and proper testing practices, the industry can protect the reputation of the plant that so many believe is improving their quality of life.


[1] https://bdsanalytics.com/top-10-cannabis-market-trends-2019/

[2] https://www.calgarycmmc.com/reliefofsymptoms.htm

[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103256/


Jessa Youngblood is the cannabis industry specialist at Hardy Diagnostics. She sits on the AOAOC CASP committee for Microbial Contaminants Working Group as well as the NCIA Scientific Advisory Committee. Jessa has a passion for safe access to cannabis medicine and regularly leads webinars and trainings to support the development of cannabis microbiology testing programs across the US and Canada.  

As an industry specialist, I have had the opportunity to speak to many different people in the cannabis market as well as interact with the incredible products that they are bringing to consumers and patients. When I see someone with a new application for cannabis, it is exciting to think of how it can impact and change lives. While I am optimistic for this bold, new industry, I am concerned at the lack of testing requirements when it comes to the finish goods. Let us join together to push forward into a more developed, safer market by addressing the hurdles we face. Reach out to others manufacturing products like yours in similar industries to learn how their processes have evolved to ensure safety. Reach out to regulatory and industry specialists to learn what steps you can take now to be prepared for the end of federal prohibition. Implementing these standards is the best way to protect the clients that use your products and your business future.

Leave a Reply

Your email address will not be published. Required fields are marked *

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
Sign Up for the Latest From the HardyBlog
Sign up for monthly updates of all the latest and greatest postings from here on the HardyBlog.
ErrorHere